Clinical Oncologist from Texas🇺🇸Director of @OncoAlert 🚨 Proudly NIH, NCI & MDA trained. An ounce of prevention equals a pound of cure. Views are own🌏
San Antonio, TX
Joined May 2009
- Tweets35.5K
- Following7.3K
- Followers16.5K
- Likes48.2K
Pinned Tweet
A pleasure to publish this at @CD_AACR w/some AMAZING @OncoAlert 🚨colleagues/friends
SoMe has immense potential in ALL areas of medicine⚕️
☑️raises awareness on trials
☑️promotes cancer prevention ☑️amplifies oncology info
☑️enables diverse viewpoints
aacrjournals.org/cancerdisco…
Check out the #ESMO26 Coverage and our NEW website👉 oncoalert360.com/events/esmo…
Visit Our New Website 🚨 Science Directly From People Who Presented It
👉 oncoalert360.com/events/esmo…
No noise. No ads. Just oncology, for colleagues, by colleagues.
OncoAlert is with you every day, not just at congresses. Our website brings you the science you need to stay up to date, with no fluff, no distractions and no advertising.
We are a non-profit Organization with one mandate: keeping colleagues worldwide up to date. For almost a decade, OncoAlert has been made 100% by physicians, by oncologists for oncologists. Some of the biggest names in oncology are part of this network, and they use it to bring new findings directly to you.
@cdanicas · @hoperugo · @DrChoueiri · @TiansterZhang · @matteolambe · @NiuSanford · @stolaney1 · @christine_lovly · @amerseburger · @GlopesMd · @tompowles1 · @montypal · @Icro_Meattini · @PGrivasMDPhD · @brian_rini · @CathyEngMD · @apolo_andrea · @AndreaNecchi · @DrSGraff · @BenWestphalen · @graokane · @to_be_elizabeth · @ElisaAgostinett · @nataliagandur · @UOzkerim · @DrMirallas · @DrYukselUrun · @Lucarecco · @mzugman · @HHorinouchi · @p_ciracimd · @DraMartinezLago · @DrVilmaPBarcia · @GIMedOnc · @MarioBalsaMD · @scocmem · @AmandaNizamMD · @GaiaGriguolo · @JankovicK · @Dr_Oncologista · @Erman_Akkus · @WeOncologists · @niklas_kluemper · @Markuseckstein3
Gil Morgan, MD retweeted
Explore timely, on-the-ground coverage of key trials presented at ESMO 2026 with VJ Oncology 👉 vjoncology.com/event/esmo-20…
Insights from leading oncology experts, recorded live at the congress by our collaborators at VJ Oncology.
Visit the @VJOncology website to watch the latest coverage.
@MiriamMerad, @GynCancerMD, @josepereag, @niazi_Dr7, @C_Ricordel, @WainbergZev, @KalinskyKevin, @sara_lonardi1, @KoheiShitara, @ProfGLongMIA, @david_tougeron, @FilippoPietran4, @VanitaNoronha, @decroisette, @abhenilmittal, @changhoon_yoo, @DrSapnaPatel, @tompowles1, @AndreaNecchi, @lab_kok, @AriRosenbergMD, @DrNeilGross, @LorenzaRimassa, @_callimaco, @RandySweisMD, @kyosuke_seguchi
Gil Morgan, MD retweeted
📢 Join us at the 44th Annual Chemotherapy Foundation Symposium (CFS®): Innovative Cancer Therapy for Tomorrow 📅 November 11–13, 2026 (NY, NY🇺🇸 )
REGISTER 👉 buff.ly/3G9pRP6
HYBRID MEETING (Online and In Person)
🚨 FREE🆓 REGISTRATION with Code: OncoAlert
For more than four decades, CFS® has been a premier educational event bringing together oncology professionals from around the world to explore the latest advances in cancer care. This 3-day conference will feature internationally renowned experts discussing practice-changing developments across solid tumors and hematologic malignancies, including targeted therapies, immunotherapies, novel biomarkers, and combination treatment strategies.
Attendees will gain valuable insights into:
🔹 Emerging biomarker-driven treatment approaches
🔹 Results from pivotal clinical trials
🔹 Personalized treatment strategies based on evolving evidence
🔹 Management of adverse events associated with novel therapies
Led by Program Co-Chairs:
• Benjamin Levy, MD
• John Mascarenhas, MD
• Tiffany Traina, MD, FASCO
Don't miss this opportunity to stay at the forefront of oncology and help shape the future of cancer care.
@KCArbourMD
@mishabeltran
@KellyLBolton
@HosseinBorghaei
@AjaiChari
@End_myeloma
@DrPinkalDesai
@FordePatrick
@MattGalsky
@YJanjigianMD
@DrHKantarjian
@montypal
@szusmani
@HelenaYu923
@gotoPER
Gil Morgan, MD retweeted
🚨 The congress may be over but the learning definitely isn’t!
The COMPLETE #ESMO26 Newsletter from @OncoAlert is OUT TODAY!!! Our faculty’s top trials, key takeaways and expert context from Madrid, all distilled into one read 📩
oncoalert.m-pages.com/nhMpwe…
Thousands of abstracts. One inbox. Zero excuses to miss the signal 😉
OUT TODAY!!
THE COMPLETE #ESMO26 NEWSLETTER 📰
Bringing together our top picks from the most important trials presented in Madrid, all in one email.
📩 Register to receive it: buff.ly/N5gYtAc
Curated by oncologists, for colleagues in cancer care, our mission is to make the latest oncology science accessible, relevant, and easy to digest.
We are OncoAlert 🚨 — For Colleagues, by Colleagues.
Best,
The OncoAlert Network
@cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists @niklas_kluemper @Markuseckstein3
Gil Morgan, MD retweeted
No #ASCO26 #HNcancer plenary 🎙️ this year but still many studies to take note of!
🗒️My list of oral presentations of interest and preliminary takeaways
💡Of course, looking forward to the presentations themselves for the ever-important details
@OncUpdates @OncBrothers @ASCO @OncoAlert
Gil Morgan, MD retweeted
Visit Our New Website 🚨 Science Directly From People Who Presented It
👉 oncoalert360.com/events/esmo…
No noise. No ads. Just oncology, for colleagues, by colleagues.
OncoAlert is with you every day, not just at congresses. Our website brings you the science you need to stay up to date, with no fluff, no distractions and no advertising.
We are a non-profit Organization with one mandate: keeping colleagues worldwide up to date. For almost a decade, OncoAlert has been made 100% by physicians, by oncologists for oncologists. Some of the biggest names in oncology are part of this network, and they use it to bring new findings directly to you.
@cdanicas · @hoperugo · @DrChoueiri · @TiansterZhang · @matteolambe · @NiuSanford · @stolaney1 · @christine_lovly · @amerseburger · @GlopesMd · @tompowles1 · @montypal · @Icro_Meattini · @PGrivasMDPhD · @brian_rini · @CathyEngMD · @apolo_andrea · @AndreaNecchi · @DrSGraff · @BenWestphalen · @graokane · @to_be_elizabeth · @ElisaAgostinett · @nataliagandur · @UOzkerim · @DrMirallas · @DrYukselUrun · @Lucarecco · @mzugman · @HHorinouchi · @p_ciracimd · @DraMartinezLago · @DrVilmaPBarcia · @GIMedOnc · @MarioBalsaMD · @scocmem · @AmandaNizamMD · @GaiaGriguolo · @JankovicK · @Dr_Oncologista · @Erman_Akkus · @WeOncologists · @niklas_kluemper · @Markuseckstein3
Gil Morgan, MD retweeted
OUT TODAY!!
THE COMPLETE #ESMO26 NEWSLETTER 📰
Bringing together our top picks from the most important trials presented in Madrid, all in one email.
📩 Register to receive it: buff.ly/N5gYtAc
Curated by oncologists, for colleagues in cancer care, our mission is to make the latest oncology science accessible, relevant, and easy to digest.
We are OncoAlert 🚨 — For Colleagues, by Colleagues.
Best,
The OncoAlert Network
@cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists @niklas_kluemper @Markuseckstein3
🤖 Made with AI
Gil Morgan, MD retweeted
Two active drugs. A closer look at what each contributes. 🎙️
In Episode 522, Anders Ullén joins the Uromigos to unpack an exploratory three-arm KEYNOTE-905 analysis in cisplatin-ineligible muscle-invasive bladder cancer, discussing pembrolizumab’s activity, the added contribution of EV, and the balance between efficacy and toxicity.
Swipe for the highlights, then hear the full discussion: bit.ly/4iv9Mro
#Uromigos #BladderCancer #ESMO26
Gil Morgan, MD retweeted
Devastating news —we were just #ESMO26 in Madrid. 42,000 people. I hope all our colleagues are safe going back from @myESMO ….
Prayers for the victims and families.
bbc.com/news/live/cv1j309d4g…
Gil Morgan, MD retweeted
Thank you Colleagues for a phenomenal #ESMO26
ESMO in Madrid is a wrap, and we are grateful to everyone who shared, discussed, debated and amplified the science this week. You turned five days in Madrid into a truly global conversation. 🌍 OUR Network's MISSION: Keep our colleagues worldwide Up To date in REAL TIME.
📣 101.7M impressions of potential reach
💬 6.1K posts on X from 988 participants in 34 countries
⚡ 43.1 posts per hour across the meeting days
😊 45% positive sentiment, with only 6% negative
Real-time metrics powered by ACUVOX. WWW.ACUVOX.IO
🏆 Top influencers
@DrChoueiri, @StephenVLiu, @PTarantinoMD, @dr_yakupergun, @HHorinouchi, @zklaassen_md, @stolaney1, @ArndtVogel, @DrYukselUrun, @DraMartinezLago, @tompowles1, @SuyogCancer, @adamfeuerstein, @ScaltritiLab, @GIMedOnc, @ScottGottliebMD, @barriere_dr, @_ShankarSiva, @miriamgonp, @TiansterZhang, @matteolambe, @NiuSanford, @christine_lovly, @amerseburger, @GlopesMd, @montypal, @Icro_Meattini, @PGrivasMDPhD, @brian_rini, @CathyEngMD, @apolo_andrea, @AndreaNecchi, @DrSGraff, @graokane, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @Lucarecco, @mzugman, @p_ciracimd, @DrVilmaPBarcia, @MarioBalsaMD, @scocmem, @GaiaGriguolo, @JankovicK, @Dr_Oncologista
🌎 Where the conversation came from
North America led with 1,940 posts, followed closely by Europe with 1,777. Boston, Madrid and New York were the most active cities.
🔬 Top studies by impact
1️⃣ DeLLphi-305 (SCLC): 4.0M reach, 170 posts
2️⃣ VOLGA (bladder): 3.7M reach, 141 posts
3️⃣ KRASCENDO-1 (NSCLC): 3.5M reach
4️⃣ SAFFRON (NSCLC): 3.3M reach
5️⃣ INTerpath-001 (melanoma): 154 posts
Pinging our Collaborators
Gil Morgan, MD retweeted
Terrific work @tompowles1! Thank you @oncoalert for amplifying.
Why ‘More Drugs’ Isn’t Always Better: VOLGA Trial Redefines #BladderCancer Care
#Podium2Screen from the #ESMO26 Presidential Session
Presented by our @OncoALert 🚨faculty @tompowles1
Perioperative Durvalumab ± Tremelimumab Plus Neoadjuvant Enfortumab Vedotin in Muscle-Invasive Bladder Cancer: Results From the Phase 3 VOLGA Trial @jteoh_hk @CPRT65
🔬 Phase 3 VOLGA trial (n=695)
Evaluated perioperative durvalumab (D) ± tremelimumab (T) plus neoadjuvant enfortumab vedotin (EV) versus control (radical cystectomy [RC], followed by observation or approved adjuvant therapy) in cisplatin-ineligible muscle-invasive bladder cancer (MIBC).
Just PUBLISHED in @NEJM
nejm.org/doi/full/10.1056/NE…
Interim analysis; median event-free survival (EFS) follow-up: 22.9 months.
➡️ D + EV: EFS HR 0.51 (95% CI, 0.38–0.67); OS HR 0.58 (95% CI, 0.40–0.83)
➡️ D + T + EV: EFS HR 0.61 (95% CI, 0.47–0.80); OS did not meet statistical significance
➡️ Pathological complete response (pCR): 45% with D + EV vs 10% with control
➡️ Grade 3/4 treatment-related adverse events (TRAEs): 30% with D + EV vs 42% with control
✅ Both primary EFS endpoints were met. Perioperative durvalumab plus 3 cycles of neoadjuvant EV also significantly improved OS.
🎙️ Presenter: Thomas Powles
👥 Investigators: Alexandra Drakaki · Jeremy Teoh · Enrique Grande · Mario Fontes-Sousa · Camillo Porta · Esther Wu · Erik Goluboff · Svetlana Ho · Stephan Hois · Ashok Gupta · James Catto
@DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @niklas_kluemper @Markuseckstein3
Gil Morgan, MD retweeted
It is exciting to see our @aron_project on Sex-based differences in clinical outcomes of enfortumab vedotin and NECTIN-4 expression in urothelial cancer published on @NatureComms
Thanks to @TarekTahaMD @MatteoSantoniMD and all my Aron friends. @OncoAlert
Gil Morgan, MD retweeted
What an #EMSO26 it has been...impossible to oversee everything that has happened.
Luckily, you'll find everything you need to know in the @OncoAlert 🚨newsletter 👇
Dear colleagues,
We are already curating THE COMPLETE #ESMO26 NEWSLETTER 📰 our picks of the top trials presented in Madrid, together in one email.
Register to receive it 👉 buff.ly/N5gYtAc
Every newsletter is curated by oncologists, for colleagues working in cancer care. It’s our way of making science quick and accessible.
We are OncoAlert🚨 For Colleagues, by Colleagues
Best,
The Network
@cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists @niklas_kluemper @Markuseckstein3
Gil Morgan, MD retweeted
New in Perspectives: Research in Context 📖 New study challenges current standards of continuous-duration therapy and suggests that many standard-risk patients with newly diagnosed multiple myeloma may be able to stop treatment after 2 years.
acsjournals.onlinelibrary.wi…
@OncoAlert
#ESMO26 by the numbers:
📣 101.7M potential reach 💬 6.1K posts, 988 participants, 34 countries 😊 45% positive, 6% negative
Science travels fastest when colleagues share it. Thank you all 🙏 Missed some of it?
Every key trial in one email 👉 buff.ly/N5gYtAc
Thank you Colleagues for a phenomenal #ESMO26
ESMO in Madrid is a wrap, and we are grateful to everyone who shared, discussed, debated and amplified the science this week. You turned five days in Madrid into a truly global conversation. 🌍 OUR Network's MISSION: Keep our colleagues worldwide Up To date in REAL TIME.
📣 101.7M impressions of potential reach
💬 6.1K posts on X from 988 participants in 34 countries
⚡ 43.1 posts per hour across the meeting days
😊 45% positive sentiment, with only 6% negative
Real-time metrics powered by ACUVOX. WWW.ACUVOX.IO
🏆 Top influencers
@DrChoueiri, @StephenVLiu, @PTarantinoMD, @dr_yakupergun, @HHorinouchi, @zklaassen_md, @stolaney1, @ArndtVogel, @DrYukselUrun, @DraMartinezLago, @tompowles1, @SuyogCancer, @adamfeuerstein, @ScaltritiLab, @GIMedOnc, @ScottGottliebMD, @barriere_dr, @_ShankarSiva, @miriamgonp, @TiansterZhang, @matteolambe, @NiuSanford, @christine_lovly, @amerseburger, @GlopesMd, @montypal, @Icro_Meattini, @PGrivasMDPhD, @brian_rini, @CathyEngMD, @apolo_andrea, @AndreaNecchi, @DrSGraff, @graokane, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @Lucarecco, @mzugman, @p_ciracimd, @DrVilmaPBarcia, @MarioBalsaMD, @scocmem, @GaiaGriguolo, @JankovicK, @Dr_Oncologista
🌎 Where the conversation came from
North America led with 1,940 posts, followed closely by Europe with 1,777. Boston, Madrid and New York were the most active cities.
🔬 Top studies by impact
1️⃣ DeLLphi-305 (SCLC): 4.0M reach, 170 posts
2️⃣ VOLGA (bladder): 3.7M reach, 141 posts
3️⃣ KRASCENDO-1 (NSCLC): 3.5M reach
4️⃣ SAFFRON (NSCLC): 3.3M reach
5️⃣ INTerpath-001 (melanoma): 154 posts
Pinging our Collaborators
Gil Morgan, MD retweeted
Dear colleagues,
Tarlatamab keeps a 38% reduction in risk of death vs chemo in relapsed SCLC. One of our top ESMO26 picks.
THE COMPLETE ESMO26 NEWSLETTER : Every key trial from Madrid, curated by oncologists, in one email. Free
OncoAlert🚨 For Colleagues, by Colleagues
🤖 Made with AI
Gil Morgan, MD retweeted
‼️ On 134 key questions in prostate cancer care, experts reached consensus on just 44.
What does that tell us about the evidence guiding treatment — and where do we need better answers?
📄 Management of Patients with High-risk Localised, Locally Advanced, and Biochemically Recurrent Prostate Cancer: Report from the 2026 Advanced Prostate Cancer Consensus Conference
🔗 sciencedirect.com/science/ar…
At #APCCC26, 144 international experts 🌐 tackled challenging clinical questions where high-level evidence remains limited.
Using a modified Delphi process, 133 panellists voted on 134 questions covering high-risk localised, locally advanced and biochemically recurrent prostate cancer, including PSA persistence, PSA recurrence and treatment-related side effects.
✅ Consensus (≥75% agreement) was reached on just 44 questions (32.8%), with strong consensus (≥90%) on only seven.
👉 Where experts disagree, the need for better evidence is clear. Areas without consensus highlight important priorities for future clinical trials.
@Silke_Gillessen, @AOmlin, @Prof_Nick_James, @LVM_Walz, @AOmlin, @AttardLab, @bjartell, @LoebStacy, @Tilki_De, @piet_ost, @Nicola_Fossati, @AnthonyMJoshua, @VedangMurthy, @neerajaiims, @Achard_Verane, @PBlanchardMD, @lisahorvath73, @BarbaraJereczek, @fontev1, @ChrisSweens1, @AarmstrongDuke, @CharlesRyanMD, @ProfKHerrmann, @KarimFizazi, @NealShore, @himishabeltran, @HeatherChengMD, @DrRanaMcKay, @AliciaMorgansMD, @declangmurphy, @DrSpratticus, @EvanYuMD, @NehaVapiwalaMD, @drjefstathiou, @BertrandTOMBAL @OncoAlert 🚨
#ProstateCancer #APCCC26
For years, cisplatin-ineligible MIBC meant surgery and hope.
VOLGA changes that‼️
perioperative durvalumab + 3 cycles of EV, with an OS benefit and less toxicity than control. And a lesson: the third drug didn't help.
Worth 5 minutes with @tompowles1 👇 #ESMO26
Why ‘More Drugs’ Isn’t Always Better: VOLGA Trial Redefines #BladderCancer Care
#Podium2Screen from the #ESMO26 Presidential Session
Presented by our @OncoALert 🚨faculty @tompowles1
Perioperative Durvalumab ± Tremelimumab Plus Neoadjuvant Enfortumab Vedotin in Muscle-Invasive Bladder Cancer: Results From the Phase 3 VOLGA Trial @jteoh_hk @CPRT65
🔬 Phase 3 VOLGA trial (n=695)
Evaluated perioperative durvalumab (D) ± tremelimumab (T) plus neoadjuvant enfortumab vedotin (EV) versus control (radical cystectomy [RC], followed by observation or approved adjuvant therapy) in cisplatin-ineligible muscle-invasive bladder cancer (MIBC).
Just PUBLISHED in @NEJM
nejm.org/doi/full/10.1056/NE…
Interim analysis; median event-free survival (EFS) follow-up: 22.9 months.
➡️ D + EV: EFS HR 0.51 (95% CI, 0.38–0.67); OS HR 0.58 (95% CI, 0.40–0.83)
➡️ D + T + EV: EFS HR 0.61 (95% CI, 0.47–0.80); OS did not meet statistical significance
➡️ Pathological complete response (pCR): 45% with D + EV vs 10% with control
➡️ Grade 3/4 treatment-related adverse events (TRAEs): 30% with D + EV vs 42% with control
✅ Both primary EFS endpoints were met. Perioperative durvalumab plus 3 cycles of neoadjuvant EV also significantly improved OS.
🎙️ Presenter: Thomas Powles
👥 Investigators: Alexandra Drakaki · Jeremy Teoh · Enrique Grande · Mario Fontes-Sousa · Camillo Porta · Esther Wu · Erik Goluboff · Svetlana Ho · Stephan Hois · Ashok Gupta · James Catto
@DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @niklas_kluemper @Markuseckstein3
Gil Morgan, MD retweeted
A little something to celebrate! 🎙️
The Uromigos podcast has been recognized by @_feedspot as one of the Top 100 Oncology Podcasts!
A BIG thank you to our incredible guests, listeners, and the global oncology community for being part of the conversation.
🎧 Join the conversation wherever you listen to podcasts!
Gil Morgan, MD retweeted
And that’s a wrap on #ESMO26! 🙌
From packed presentation halls to discussions about the latest data, there has been plenty to take in.
Also a great opportunity to catch up with Dr. Daan De Maeseneer and Dr. Daniele Raggi, two GU oncology experts, and hear their perspectives on some of the highlights from this year’s meeting.
A perfect way to wrap up a busy and inspiring few days. Until next time, ESMO! 👋
